SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos Pizza is drawing attention after its Q4 earnings report showcased solid results and strategic investments, further amplified by Berkshire Hathaway's increased stake. The community is actively debating if its focus on value and digital initiatives can continue to drive market share in a competitive restaurant environment.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating high efficacy and potential disease-modifying effects. This positive data, coupled with a major institutional investor significantly increasing its stake and an anticipated Investor Day, has ignited strong community discussion about its "best-in-class" potential, a potential re-rating, and a short squeeze.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the community processes its solid Q4 earnings beat against conservative 2026 guidance, alongside significant M&A activity including the Arcellx acquisition and key patent settlements for its dominant HIV franchise. Investors are also closely watching developments in its oncology pipeline, such as recent Trodelvy trial results, amid discussions about the company's long-term growth trajectory in a volatile market.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals is trending after securing a significant patent victory for its Nuplazid drug, ensuring market exclusivity and prompting multiple analyst upgrades. The community is actively discussing the company's robust, potentially undervalued pipeline in neurological and rare diseases, balancing this against recent EU regulatory challenges for its Rett syndrome treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Windtree Therapeutics Inc. drew increased retail chatter on Tuesday after disclosing plans to adopt a cryptocurrency policy that would enable it to accept digital currencies as payment and hold them as assets.The stock closed at $0.79, up 5% on Tuesday, but declined 4.9% to $0.75 in after-hours trading.The biotech firm said its board approved the development of the policy, which aims to align with broader digital commerce trends.&nbsp;The move comes as the company pursues a transition toward a revenue-generating model.Windtree added that it is in discussions with several groups that focus on Bitcoin and other cryptocurrencies as potential payment options.&nbsp;The company also said it may hold long-term digital assets as part of a broader treasury strategy.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.One user noted increased buying interest in Windtree, citing low float and crypto-related news.&nbsp;<stembedurl>https://stocktwits.com/makedatbread88/message/616696047</stembedurl>Meanwhile, another user expressed skepticism, saying they had never seen a stock that consistently declines.<stembedurl>https://stocktwits.com/Lord_Andrew_London/message/616705134</stembedurl>The stock has declined 95.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representation of Bitcoin, Ripple, Litecoin and Ethereum cryptocurrencies is seen in this illustration photo taken in Krakow, Poland on June 6, 2021. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Windtree Stock Falls After-Hours As Board Approves Crypto Policy Amid Revenue Diversification Efforts

The company plans to accept and hold cryptocurrencies and is in talks with several groups focused on digital payments.

Equity

U.S. stocks rose on Friday morning as investors digested the latest inflation data, which reinforced expectations of a September interest rate cut. The broader market exhibited a mixed performance in the previous session, with early optimism stemming from strong GDP data fading as tech giants dragged down the Nasdaq and S&amp;P 500.Here’s a look at the top three stocks that captured retail investors’ attention ahead of the opening bell today:Windtree Therapeutics Inc (WINT)<figure class="image"><a href="https://stocktwits.com/symbol/WINT"><img style="aspect-ratio:1316/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/WINT_sentiment_and_message_volume_score_on_Jul_26_58f5cea25d.png" alt="WINT sentiment and message volume score on Jul 26.png" width="1316" height="320"></a><figcaption>WINT sentiment and message volume score premarket on Jul 26</figcaption></figure>Shares of Windtree Therapeutics surged by an impressive 150% in pre-market trading to reach a high $9.40. The biopharma company announced an update on its novel heart failure treatment, istaroxime, igniting a buying frenzy among retail investors.&nbsp;Stocktwits data revealed overwhelmingly bullish sentiment (71/100), with message volume reaching its highest level this year (90/100). While the stock has experienced a significant decline of over 73% year-to-date, today's surge has injected a dose of optimism among investors.Dexcom Inc (DXCM)In stark contrast to Windtree's performance, Dexcom Inc witnessed a dramatic decline of over 36% in pre-market trading, settling in the mid $60s. The medical device company's disappointing second-quarter revenue results and a weak FY24 revenue guidance for its glucose monitoring devices triggered a sell-off. Despite the price drop, several analysts maintained price targets well above current levels, suggesting potential upside in the long term.&nbsp;However, retail investor sentiment on Stocktwits plummeted to its lowest point this year (10/100), reflecting the bearish outlook, while message volumes reached a 2024 peak (96/100). Concerns about management’s inability to adequately communicate business issues and its plan to fix it, as well as market share impacts from the adoption of GLP-1 weight loss drugs is keeping retail away. &nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:1324/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DXCM_sentiment_and_message_volume_score_on_Jul_26_17d563e160.png" alt="DXCM sentiment and message volume score on Jul 26.png" width="1324" height="314"></a><figcaption>DXCM sentiment and message volume score premarket on Jul 26</figcaption></figure>Anavex Life Sciences Corporation (AVXL)Shares of Anavex Life Sciences Corporation climbed over 4% in pre-market trading to a high of $7.22, with retail sentiment on Stocktwits at bullish levels (65/100).&nbsp;The neuro-disease-focused biopharma company received a boost from EF Hutton analyst Jason Kolbert, who initiated coverage with a Buy rating and a price target of $46. The analyst highlighted the company's lead therapy, ANAVEX2-73, for Alzheimer's Disease (AD), which is on track for regulatory submission by the end of the year. The potential market for ANAVEX2-73, coupled with its broader therapeutic applications, has fueled investor optimism.<figure class="image"><a href="https://stocktwits.com/symbol/AVXL"><img style="aspect-ratio:1320/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_sentiment_and_message_volume_score_on_Jul_26_d22a8e0bab.png" alt="AVXL sentiment and message volume score on Jul 26.png" width="1320" height="312"></a><figcaption>AVXL sentiment and message volume score premarket on Jul 26</figcaption></figure><a href="https://www.vecteezy.com/photo/29286690-ai-generative-business-man-standing-in-the-stock-market-realistic-image-ultra-hd-high-design-very-detailed">Photo</a> courtesy of syedqaseem on Vecteezy

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Before the Bell

Two stocks are sparking optimism on Stocktwits with watchers passionately discussing potential catalysts, while one is losing a lot of favor following its disappointing earnings and outlook. 

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Premarket

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

WINT
Windtree Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest WINT News

WINTWindtree Therapeutics Inc